Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naïve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis.
Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naïve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis.
复制标题
基于多拉韦林的三种药物方案对初治 HIV-1 阳性成人的疗效和安全性比较：贝叶斯网络荟萃分析
DOI：
10.3389/fphar.2022.676831
复制
发表时间：
2022
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
前言：抗逆转录病毒治疗的广泛应用显著提高了艾滋病毒携带者的存活率。多拉韦林(DOR)是新近批准的一种抗逆转录病毒药物，属于非核苷类逆转录酶抑制剂。在这里，我们比较了DOR+替诺福韦富马酸酯(TDF)+拉米夫定(3TC)/恩曲他滨(FTC)与传统三联疗法治疗初治HIV-1阳性成人的疗效和安全性。方法：系统检索符合纳入标准的治疗初治HIV-1阳性成人的随机对照试验，并提取关于以下结果的数据：病毒学抑制、不良事件、严重不良事件和药物相关不良事件。然后对数据进行贝叶斯网络荟萃分析。结果：这项研究共纳入39项随机对照试验，涉及26种抗逆转录病毒疗法和21,110名HIV1阳性患者。在48周时，相对于纳入病毒抑制网络的其他25个方案，DOR+TDF+3TC/FTC显示出优于一些基于Eefavirenz、neviRapine、atazanavir或Lopinavir的方案，包括Eefavirenz+Aabacavir+3TC[奇比(OR)=0.52，95%可信区间(CRI)=0.35~0.77]。在48周时，DOR+TDF+3TC/FTC在不良事件方面的表现与所有其他被分析的方案相对相似。DOR+TDF+3TC/FTC方案在严重不良事件和药物相关不良事件方面表现较好。结论：网络Meta分析显示，DOR+TDF+3TC/FTC治疗48周有良好的疗效和安全性。系统评价注册：开放科学框架，https://osf.io/6ybp7.
Introduction: Extensive use of antiretroviral therapy has remarkably improved the survival rates of people living with HIV. Doravirine (DOR) is a newly-approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors. Here, we compared the efficacy and safety of DOR + tenofovir dipivoxil fumarate (TDF)+Lamivudine (3TC)/Emtritabine (FTC) with traditional triple therapies in treatment-naïve HIV-1-positive adults. Methods: Randomized controlled trials involving treatment-naïve HIV-1-positive adults that met inclusion criteria were systematically retrieved and data on the following outcomes extracted: virological suppression, adverse events, severe adverse events, and drug-related adverse events. A Bayesian network meta-analysis was then performed on the data. Results: This study included a total of 39 randomized controlled trials involving 26 antiretroviral therapies and 21,110 HIV1-positive patients. At week 48, relative to the other 25 regimens included in the network of virological suppression, DOR + TDF+3TC/FTC exhibited superiority to some efavirenz, nevirapine, atazanavir, or lopinavir-based regimens, including efavirenz + abacavir+3TC [Odd Ratio (OR) = 0.52, 95% confidence interval (CrI) = 0.35–0.77]. At week 48, the performance of DOR + TDF+3TC/FTC was relatively similar to all other analyzed regimens in terms of adverse events. The DOR + TDF+3TC/FTC regimen performed better in terms of severe adverse events and drug-related adverse events. Conclusion: The network meta-analysis showed that DOR + TDF+3TC/FTC has good efficacy and safety at 48 weeks. Systematic Review Registration: Open Science Framework, https://osf.io/6ybp7.
登录
查看更多内容
DOI：
10.1097/qad.0000000000001817
发表时间：
2018-07-17
期刊：
AIDS (London, England)
影响因子：
--
作者：
Eron JJ;Orkin C;Gallant J;Molina JM;Negredo E;Antinori A;Mills A;Reynes J;Van Landuyt E;Lathouwers E;Hufkens V;Jezorwski J;Vanveggel S;Opsomer M;AMBER study group
通讯作者：
AMBER study group
影响因子：
11.8
作者：
DeJesus, E;Herrera, G;Scott, TR
通讯作者：
Scott, TR
DOI：
10.1111/j.1742-1241.2011.02807.x
发表时间：
2011-12-01
影响因子：
2.6
作者：
DeJesus, E.;Mills, A.;Storfer, S.
通讯作者：
Storfer, S.
影响因子：
39.2
作者：
Lennox, Jeffrey L.;Landovitz, Raphael J.;Currier, Judith S.
通讯作者：
Currier, Judith S.
影响因子：
39.2
作者：
Hutton, Brian;Salanti, Georgia;Moher, David
通讯作者：
Moher, David